Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer

BACKGROUND: Castration resistant prostate cancer (CRPC) is a leading cause of cancer-related deaths in men. The primary cause of mortality and morbidity in patients is bone metastases and remodeling resulting in osteoblastic and osteolytic lesions. Recently, cabozantinib, a multi-kinase inhibitor (V...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Eswaraka, Jeetendra, Giddabasappa, Anand, Han, Guangzhou, Lalwani, Kush, Eisele, Koleen, Feng, Zheng, Affolter, Timothy, Christensen, James, Li, Gang
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2014
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4190397/
https://ncbi.nlm.nih.gov/pubmed/25277255
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-742
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi